Prostate artery embolisation (PAE) is a minimally invasive alternative to surgical resection, which aims to shrink the prostate gland rather than remove it. In PAE, an interventional radiologist inserts a catheter into the femoral artery at the top of the leg, and guides the catheter to the prostate arteries. A solution of microscopic particles is injected through the catheter, which mechanically block the prostate arteries and partially reduce the blood supply. There are four different types of embolisation agents (all CE-marked, none with FDA approval) that can be used in PAE, which vary in size and material. A total of three comparative studies with 306 patients are available for analysis of efficacy; the included RCTs make contradictory statements regarding improvements in IPSS and HRQoL after 12 months. The most commonly reported side effects associated with PAE in all studies were minor. Currently, five RCTs are ongoing comparing PAE to TURP, the end of which is scheduled for February 2021. A new evaluation is proposed in the year 2021, if results from RCTs are available.